Evolving Treatment Paradigms in Advanced Prostate Cancer; Individualizing Treatment Strategies Based on Advancing Clinical Data

Evolving Treatment Paradigms in Advanced Prostate Cancer; Individualizing Treatment Strategies Based on Advancing Clinical Data
Please join us for a CME/CE Accredited Luncheon Symposium at the 47th Kimbrough Annual Meeting

Date: Saturday, January 13, 2018
Time: 11:30am-1:00pm
Location: The Scottsdale Resort at the McCormick Ranch
                  7700 E. McCormick Parkway
                  Scottsdale, AZ
                  Coronado Ballroom

Program Summary

The concurrent development of many treatments for advanced prostate cancer (APC) within a short period of time has made prospective data on their sequential use and efficacy complicated. Increasingly complex prostate cancer treatment milieu is marked by limited sequencing or combination trials, an increasingly complex understanding of disease pathophysiology and genomic profiling, and emerging therapeutics with novel mechanisms of action. Understanding the available treatments, both current and emerging, and how these agents interface with disease pathophysiology to drive a more personalized medicine approach remains significant challenges for clinicians who treat patients with advanced prostate cancer including urologists and oncologists in government service.

This luncheon satellite symposium is designed to meet the educational needs of government service urology and oncology professionals involved in the treatment of retired and active military personnel with advanced prostate cancer. 
Educational Objectives 

This education programming is designed to provide government service urologists and oncologists in the general population with the latest developments and critical insights into the management of advanced prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application. To narrow the identified practice gaps and underlying educational needs, the following objectives will be addressed within the proposed educational activities.

1.  Assess the latest evidence-based management strategies for patients with advanced prostate cancer (APC) through integration of available hormonal, cytotoxic, and immunotherapeutic agents, including relevant sequencing considerations

2.  Evaluate the risks and benefits of novel approaches to treatment, including the emerging role of biomarkers in men with APC

3.  Implement best practice strategies to minimize or manage disease and treatment-associated complications

4.  Apply shared decision making resources (SDM) to improve collaboration with clinician and patient in order to provide optimal outcomes by providing best standard of care
Accreditation Information

Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Rush University Medical Center designates this Live Activity for a maximum of one (1) AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Rush University designates this live activity for one (1) Continuing Education credits. This activity will fulfill Category 1 contact hour requirements for pharmacology for ANCC certified advanced practice nurses.

This program is approved for 1.0 hours (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

There is no fee for participating in this activity. Pre-registration is not required.

Program Endorsers
The Association of VA Hematology/Oncology (AVAHO) and the Society of Government Service Urologists (SGSU)

Program Sponsors
This activity is co-provided by Rush University and PleXus Communications.

Matthew B. Rettig, MD
Medical Oncologist
Ronald Reagan UCLA Medical Center and VA Greater Los Angeles Healthcare System
This activity is supported by educational grants from Astellas Scientific and Medical Affairs, Inc. and Medivation, Inc., a Pfizer company, Clovis Oncology, Inc., Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC, and Tolmar Pharmaceuticals, Inc.
Click "REGISTER" to attend the program

Categories: Symposia